Upfront Payments by Therapeutic Category
One way a biotech might choose a therapeutic area of focus is by the value it could extract from a licensee. To get a handle on this value, we ranked the top therapeutic categories by total upfront money paid over the last 12 months, both in terms of equity and straight cash.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.